Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. G. Huang, Q. J. Cheng, M. R. Sears (Shanghai, China; Hamilton, Canada). As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study. Eur Respir J 2014; 44: Suppl. 58, 2425

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy of Levodropropizine: 2 metanalysis in pediatric and adult population Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy of carbamazepine in treatment of bronchial asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014